PILOT - Pulmonary Education for Health Care Providers

Page 8 of 10

Results 526 - 600 of 678

How Pulmonary Arterial Hypertension Has Changed Iain’s Life

SMA: Data, Insights and Practice

From Bench to Bedside: Gene Therapy Approaches for Rare Diseases

Biosimilars: Applying the Science to Hematology/Oncology Practice

Management of Mycobacterium Abscessus Lung Disease

Difficult to Treat Mycobacterium Avium Complex Lung Disease

Management of Mycobacterium Avium Complex Lung Disease

The Latest from a Recent Pulmonary Conference in San Antonio

Updates in Inoperable CTEPH

The Importance of Early Integration of Palliative Care

Management of IPF Patients in 2018

Updates in the Diagnosis of ILD and the Role of Cryobiopsy

Overview of the Latest Clinical Trials in IPF

Evolution of Antifibrotic Therapy in IPF

Take Home Messages from the 2018 CHEST Annual Meeting

What We’re Learning from the IPF-PRO Registry

Comparing the 2017 Fleischner Society Guidelines and the 2018 ATS Guidelines

Emerging Treatments for NTM Lung Disease

Nontuberculous Mycobacteria Case 2: Alan

NTM_and_Treatment_Strategies_for_Patients_264x150

NTM and Treatment Strategies for Patients with Cavitary Disease

New_Findings_in_the_Treatment_of_MAC_264x150

New Findings in the Treatment of MAC Lung Disease

Why_You_Should_Pay_Attention_to_NTM_264x150

Why You Should Pay Attention to NTM Treatment Guidelines

Which_of_Your_Patients_Are_at_Risk_for_NTM_264x150

Which of Your Patients Are at Risk for NTM?

Practice_Improvement_through_ILD_Centers_264x150

Practice Improvement through ILD Centers and Community Partnerships

Improving_the_Care_for_IPF_Patients_264x150

Improving the Care for IPF Patients Using a Team-Based Approach

An_Early_Integrated_Palliative_Care_264x150

An Early Integrated Palliative Care Delivery Model for Patients with IPF

Treatment Challenges with MAC Lung Disease

Nontuberculous Mycobacteria: Summary

Treatment Challenges with MABC Lung Disease

Nontuberculous Mycobacteria Case 1: Maria

NTM – To Treat or Not to Treat

Goals of NTM Treatment

Guideline-recommended Treatments for NTM

Diagnosis of NTM

Factors Associated with Respiratory Involvement in NTM

Most Common Species in NTM Lung Disease

Nontuberculous Mycobacteria: Introduction and Epidemiology

What’s New in Spinal Muscular Atrophy? Reporting from Dallas

Atopic Dermatitis: Putting it Together (Dermatology)

Atopic Dermatitis: Putting it Together (Primary Care)

atopic-derm2 copy

Atopic Dermatitis: Recent and Emerging Therapies

An Introduction to Atopic Dermatitis

New Therapies, New Opportunities and New Challenges in Managing NTM

Updates in Inoperable CTEPH

SMA Updates from Los Angeles

PAH Today: Mastering Current, Tailored Treatment

Achieving Better Control of Severe Asthma

asthma-uncontrol icon

A Personalized Approach to Managing Uncontrolled Asthma

Updates in SMA and Gene Therapy from Arlington, VA

Proper_Use_of_an_Inhaler_264x150

Proper Use of an Inhaler

biosims-archmed icon23

Top Questions about Biosimilars in Dermatology

biosims-archmed icon1

Top Questions about Biosimilars in Gastroenterology

biosims-archmed icon2

Top Questions about Biosimilars in Rheumatology

biosims-archmed icon

Top Questions about Biosimilars in Hematology/Oncology

biosims-gastro2

Biosimilars and Patients with Inflammatory Bowel Disease

Nontuberculous Mycobacterial Lung Disease Today and Tomorrow

Exploring the Patient Journey with Problem-Based Learning

Genetics and Personalized Medicine for Patients with Pulmonary Fibrosis

Environmental Influences on the Development of Pulmonary Fibrosis

Gene Abnormalities and ILD

Exploring the Basic Mechanisms that Contribute to Development of Lung Fibrosis

Updates on Registry Enrollment and Growth of the Care Center Network

New Approaches to the Diagnosis of IPF

Exploring New Therapeutic Avenues for Managing PF

New Research on Mechanisms in the Development of PF

biosims-gastro1

Biosimilars: The New Era of Gastroenterology Management Considerations

Know Before You Go: IPF Grand Rounds Pre-learning

IPF Management Considerations

Perspectives on Side Effect Management

The Latest in IPF: Implications for Clinical Practice

Registry Data Provide Important Severity Indicators for PH

New Developments in the Diagnosis and Management of IPF

Palliative Care for Patients with IPF

Real World Experience in Patients with COPD

ICD-10 Codes and Nomenclature for Classification of PAH

Page 8 of 10